Am J Physiol Cell Physiol Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Cell Physiol (November 29, 2006). doi:10.1152/ajpcell.00510.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/4/C1323    most recent
00510.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Osborn, T. M.
Right arrow Articles by Stossel, T. P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osborn, T. M.
Right arrow Articles by Stossel, T. P
Submitted on October 2, 2006
Accepted on November 23, 2006

Modifications of Cellular Responses to Lysophosphatidic Acid (LPA) and Platelet Activating Factor (PAF) by Plasma Gelsolin (pGSN)

Teresia Magnuson Osborn1*, Claes Dahlgren2, John H Hartwig3, and Thomas P Stossel3

1 Translational Medicine Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States; Department of Rheumatology and Inflammation Research, Gothenburg University, Gothenburg, Sweden
2 Department of Rheumatology and Inflammation Research, Gothenburg University, Gothenburg, Sweden
3 Translational Medicine Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States

* To whom correspondence should be addressed. E-mail: tmagnuson{at}rics.bwh.harvard.edu.

Gelsolin is a highly conserved intracellular actin-binding protein with an extracellular isoform, plasma gelsolin (pGSN). Blood concentrations of pGSN decrease in response to diverse tissue injuries. Depletion of pGSN to critical levels precedes and often predicts complications of injuries such as lung permeability changes and death. Administration of recombinant pGSN ameliorates such complications and reduces mortality in animal models. One proposed mechanism for pGSNs protective effects is that it inhibits inflammatory mediators generated during primary injuries, since pGSN binds bioactive mediators, including lysophospatidic acid (LPA) and endotoxin in vitro. However, no direct evidence in support of this hypothesis has been available. Here we show that recombinant pGSN modestly inhibited LPA-induced P-selectin up-regulation by human platelets in the presence of albumin (P < 0.0001). However, physiologically relevant pGSN concentrations inhibit platelet activating factor (PAF)-mediated P-selectin expression by up to 77% (P < 0.0001). pGSN also markedly inhibited PAF-induced superoxide anion (O2-) production of human peripheral neutrophils (PMN) in a concentration-dependent manner (P < 0.0001). A phospholipid-binding peptide derived from pGSN (QRLFQVKGRR) also inhibited PAF-mediated O2- generation (P = 0.024). Therefore pGSN interferes with PAF- and LPA- induced cellular activation in vitro, suggesting a mechanism for the protective role of pGSN in vivo.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.